Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
2202- SK,    Enhancing Tumor Therapy of Fe(III)-Shikonin Supramolecular Nanomedicine via Triple Ferroptosis Amplification
- in-vitro, Var, NA
Iron↑, Ferroptosis↑, pH↝, H2O2↑, ROS↑, Fenton↑, GSH↓, GPx4↓, lipid-P↑,
2218- SK,    Shikonin Alleviates Endothelial Cell Injury Induced by ox-LDL via AMPK/Nrf2/HO-1 Signaling Pathway
- in-vitro, Nor, HUVECs
*Dose↝, *Apoptosis↓, *Casp3↓, *Bcl-2↑, *Inflam↓, *VCAM-1↓, *ICAM-1↓, *E-sel↓, *ROS↓, *SOD↑, *AMPK↑, *NRF2↑, *HO-1↑, *TNF-α↓, *IL1β↓, *IL6↓,
3051- SK,    Resveratrol mediates its anti-cancer effects by Nrf2 signaling pathway activation
- Review, Var, NA
Nrf1↑, Apoptosis↑, TumCP↓, eff⇅, chemoP↑, eff↑, VCAM-1↓, Hif1a↓,
3045- SK,    Cutting off the fuel supply to calcium pumps in pancreatic cancer cells: role of pyruvate kinase-M2 (PKM2)
- in-vitro, PC, MIA PaCa-2
ECAR↓, Glycolysis↓, ATP↓, PKM2↓, TumCMig↓, Ca+2↑, GlucoseCon↓, lactateProd↓, MMP↓, ROS↑,
3044- SK,    Shikonin Inhibits Non-Small-Cell Lung Cancer H1299 Cell Growth through Survivin Signaling Pathway
- in-vitro, Lung, H1299 - in-vitro, Lung, H460
TumCP↓, survivin↓, TumCCA↓, CDK2↓, CDK4↓, XIAP↓, Casp3↑, Casp9↑, cycD1/CCND1↓, cycE/CCNE↓,
3043- SK,    Shikonin Induces Apoptosis by Inhibiting Phosphorylation of IGF-1 Receptor in Myeloma Cells.
- in-vitro, Melanoma, RPMI-8226
IGF-1↓, Apoptosis↑, TumCCA↑, MMP↓, Casp3↑, P53↑, BAX↑, Mcl-1↓, EGFR↓, Src↑, KDR/FLK-1↓, p‑IGF-1↓, PI3K↓, Akt↓,
3042- SK,    The protective effects of Shikonin on lipopolysaccharide/D -galactosamine-induced acute liver injury via inhibiting MAPK and NF-kB and activating Nrf2/HO-1 signaling pathways
- in-vivo, Nor, NA
*TNF-α↓, *IL1β↓, *IL6↓, *IFN-γ↓, *ALAT↓, *AST↓, *MPO↓, *ROS↓, *JNK↓, *ERK↓, *p38↓, *NF-kB↓, *p‑IKKα↓, *SOD↑, *GSH↑, *HO-1↑, *NRF2↑, *hepatoP↑,
3041- SK,    Promising Nanomedicines of Shikonin for Cancer Therapy
- Review, Var, NA
Glycolysis↓, TAMS↝, BioAv↓, Half-Life↝, P21↑, ERK↓, ROS↑, GSH↓, MMP↓, TrxR↓, MMP13↓, MMP2↓, MMP9↓, SIRT2↑, Hif1a↓, PKM2↓, TumCP↓, TumMeta↓, TumCI↓,
3040- SK,    Pharmacological Properties of Shikonin – A Review of Literature since 2002
- Review, Var, NA - Review, IBD, NA - Review, Stroke, NA
*Half-Life↝, *BioAv↓, *BioAv↑, *BioAv↑, *Inflam↓, *TNF-α↓, *other↑, *MPO↓, *COX2↓, *NF-kB↑, *STAT3↑, *antiOx↑, *ROS↓, *neuroP↑, *SOD↑, *Catalase↑, *GPx↑, *Bcl-2↑, *BAX↓, cardioP↑, AntiCan↑, NF-kB↓, ROS↑, PKM2↓, TumCCA↑, Necroptosis↑, Apoptosis↑, DNAdam↑, MMP↓, Cyt‑c↑, LDH↝,
3046- SK,    Shikonin attenuates lung cancer cell adhesion to extracellular matrix and metastasis by inhibiting integrin β1 expression and the ERK1/2 signaling pathway
- in-vitro, Lung, A549
TumCP↓, TumCI↓, TumCMig↓, p‑ERK↓, ITGB1↓,
3047- SK,    Shikonin suppresses colon cancer cell growth and exerts synergistic effects by regulating ADAM17 and the IL-6/STAT3 signaling pathway
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW48
TumCG↓, p‑STAT3↓, ADAM17↓, Apoptosis↑, Casp3↑, cl‑PARP↑, cycD1/CCND1↓, cycE/CCNE↓, TumCCA↑, JAK1?, p‑JAK1↓, p‑JAK2↓, p‑eIF2α↑, eff↓, ROS↑, IL6↓,
3048- SK,    Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, 4T1 - in-vitro, Nor, MCF12A - in-vivo, NA, NA
tumCV↓, selectivity↑, EMT↓, TumCMig↓, TumCI↓, E-cadherin↑, N-cadherin↓, Vim↓, Snail↓, β-catenin/ZEB1↓, GSK‐3β↑,
3049- SK,    Shikonin Attenuates Chronic Cerebral Hypoperfusion-Induced Cognitive Impairment by Inhibiting Apoptosis via PTEN/Akt/CREB/BDNF Signaling
- in-vivo, Nor, NA - NA, Stroke, NA
*neuroP↑, *p‑PTEN↓, *p‑Akt↑, *Bcl-2↑, *BAX↓, *cognitive↑, *BDNF↑,
3050- SK,    Systemic administration of Shikonin ameliorates cognitive impairment and neuron damage in NPSLE mice
- in-vivo, Nor, NA
*Inflam↓, *neuroP↑, *cognitive↑,
2469- SK,    Shikonin induces the apoptosis and pyroptosis of EGFR-T790M-mutant drug-resistant non-small cell lung cancer cells via the degradation of cyclooxygenase-2
- in-vitro, Lung, H1975
Apoptosis↑, Pyro↑, Casp↑, cl‑PARP↑, GSDME↑, ROS↑, COX2↓, PDK1↓, Akt↓, ERK↓, eff↓, eff↓, eff↑,
2470- SK,    PKM2/PDK1 dual-targeted shikonin derivatives restore the sensitivity of EGFR-mutated NSCLC cells to gefitinib by remodeling glucose metabolism
- in-vitro, Lung, H1299
PKM2↓, PDK1↓, Glycolysis↓,
5102- SK,  GEM,    Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway
TumCG↓, ChemoSen↑, NF-kB↓, PCNA↓, Ki-67↓, p‑EGFR↓, ROS↑, TumCCA↑, P53↑, JNK↑, Akt↓,
5103- SK,    Attenuation of PI3K-Akt-mTOR Pathway to Reduce Cancer Stemness on Chemoresistant Lung Cancer Cells by Shikonin and Synergy with BEZ235 Inhibitor
- in-vitro, NSCLC, A549
CSCs↓, TumCP↓, Nanog↓, OCT4↓, p‑Akt↓, P70S6K↓, PI3K↓, mTOR↓, eff↑,
5101- SK,    Shikonin induces colorectal carcinoma cells apoptosis and autophagy by targeting galectin-1/JNK signaling axis
- vitro+vivo, CRC, SW-620 - vitro+vivo, CRC, HCT116
Apoptosis↑, TumAuto↑, Gal1↑, TumCP↓, ROS↑, eff↑,
5100- SK,    Shikonin-induced necroptosis in nasopharyngeal carcinoma cells via ROS overproduction and upregulation of RIPK1/RIPK3/MLKL expression
- vitro+vivo, NPC, NA
TumCP↓, RIP1↑, ROS↑, Necroptosis↑, Casp3↑, Casp8↑, eff↓, TumCG↓,
5104- SK,    Shikonin induces cell cycle arrest in human gastric cancer (AGS) by early growth response 1 (Egr1)-mediated p21 gene expression.
- in-vitro, GC, AGS
TumCP↓, TumCCA↑, P21↑,
1342- SK,    RIP1 and RIP3 contribute to shikonin-induced DNA double-strand breaks in glioma cells via increase of intracellular reactive oxygen species
- in-vitro, GBM, NA - in-vivo, NA, NA
RIP1↑, RIP3↑, DNAdam↑, ROS↑, GSH↓,
1343- SK,    Simple ROS-responsive micelles loaded Shikonin for efficient ovarian cancer targeting therapy by disrupting intracellular redox homeostasis
- in-vitro, Ovarian, A2780S - in-vivo, NA, A2780S
*BioAv↓, ROS↑, GSH↓, TumCG↓,
1344- SK,    Novel multiple apoptotic mechanism of shikonin in human glioma cells
- in-vitro, GBM, U87MG - in-vitro, GBM, Hs683 - in-vitro, GBM, M059K
ROS↑, GSH↓, MMP↓, P53↑, cl‑PARP↑, Catalase↓, SOD1↑, Bcl-2↓, BAX↑, eff↓,
1345- SK,    The Critical Role of Redox Homeostasis in Shikonin-Induced HL-60 Cell Differentiation via Unique Modulation of the Nrf2/ARE Pathway
- in-vitro, AML, HL-60
CD14↑, CD11b↑, ROS↑, GSH↓, GSH/GSSG↓, GPx↑, Catalase↓, Diff↑,
1346- SK,    An Oxidative Stress Mechanism of Shikonin in Human Glioma Cells
- in-vitro, GBM, U87MG - in-vitro, GBM, Hs683
NRF2↓, ROS↑, Apoptosis↑, Cyt‑c↑, GSH↓, MMP↓, P53↑, HO-1⇅,
1312- SK,    Shikonin induces apoptosis through reactive oxygen species/extracellular signal-regulated kinase pathway in osteosarcoma cells
- in-vitro, OS, 143B
ROS↑, p‑ERK↑, Bcl-2↓, cl‑PARP↑, Apoptosis↑, TumCCA↑, Bcl-2↑, proCasp3↓,
2009- SK,    Necroptosis inhibits autophagy by regulating the formation of RIP3/p62/Keap1 complex in shikonin-induced ROS dependent cell death of human bladder cancer
- in-vitro, Bladder, NA
TumCG↓, selectivity↑, *toxicity∅, Necroptosis↑, ROS↑, p62↑, Keap1↑, *NRF2↑, eff↑,
2008- SK,  Cisplatin,    Enhancement of cisplatin-induced colon cancer cells apoptosis by shikonin, a natural inducer of ROS in vitro and in vivo
- in-vitro, CRC, HCT116 - in-vivo, NA, NA
ChemoSen↑, selectivity↑, i-ROS↑, DNAdam↑, MMP↓, TumCCA↑, eff↓, *toxicity↓,
2007- SK,    Shikonin Directly Targets Mitochondria and Causes Mitochondrial Dysfunction in Cancer Cells
- in-vitro, lymphoma, U937 - in-vitro, BC, MCF-7 - in-vitro, BC, SkBr3 - in-vitro, CRC, HCT116 - in-vitro, OS, U2OS - NA, Nor, RPE-1
tumCV↓, selectivity↑, Dose↝, other↑, MMP↓, ROS↑, DNAdam↑, Ca+2↑, Casp9↑, Cyt‑c↑, *toxicity↓,
2010- SK,    Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway
- in-vitro, Lung, H1975 - in-vitro, Lung, H1650 - in-vitro, Nor, CCD19
EGFR↓, selectivity↑, Casp↑, PARP↑, Apoptosis↑, ROS↑, eff↓, selectivity↑,
2011- SK,    Shikonin Attenuates Acetaminophen-Induced Hepatotoxicity by Upregulation of Nrf2 through Akt/GSK3β Signaling
- in-vitro, Nor, HL7702 - in-vivo, Nor, NA
*NRF2↑, *hepatoP↑, *ALAT↓, *AST↓, *MPO↓, *ROS↓, *GSH↑,
1280- SK,    Shikonin Induces Apoptotic Cell Death via Regulation of p53 and Nrf2 in AGS Human Stomach Carcinoma Cells
- in-vitro, GC, AGS
ROS↑, Casp3↑, P53↑, NRF2↓,
1281- SK,    Enhancement of NK cells proliferation and function by Shikonin
- in-vivo, Colon, Caco-2
Perforin↑, GranB↑, p‑ERK↑, p‑Akt↑, NK cell↑, eff↝,
1284- SK,    Shikonin induces ferroptosis in multiple myeloma via GOT1-mediated ferritinophagy
- in-vitro, Melanoma, RPMI-8226 - in-vitro, Melanoma, U266
Ferroptosis↑, LDH↓, ROS↑, Iron↑, lipid-P↑, ATP↓, HMGB1↓, GPx4↓, MDA↑, SOD↓, GSH↓,
977- SK,    A novel antiestrogen agent Shikonin inhibits estrogen-dependent gene transcription in human breast cancer cells
- in-vitro, BC, T47D - in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7 - in-vitro, Nor, HMEC
TumCG↓, ERα/ESR1↓, selectivity↑, *toxicity↓,
965- SK,    Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1α signaling
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW-620
Hif1a↓, ROS↓, mTOR↓, p70S6↓, 4E-BP1↓, eIF2α↓, TumCCA↑, TumCP↓, Half-Life↝,
1050- SK,    Shikonin improves the effectiveness of PD-1 blockade in colorectal cancer by enhancing immunogenicity via Hsp70 upregulation
- in-vitro, Colon, CT26
HSP70/HSPA5↑, ROS↑, PKM2↓,
1073- SK,  Chemo,    Natural Compound Shikonin Is a Novel PAK1 Inhibitor and Enhances Efficacy of Chemotherapy against Pancreatic Cancer Cells
- in-vitro, PC, PANC1 - in-vitro, PC, Bxpc-3
PAK1↓, TumCP↓, Apoptosis↑, ChemoSen↑, ROS↑,
1049- SK,    Shikonin inhibits immune checkpoint PD-L1 expression on macrophage in sepsis by modulating PKM2
- in-vivo, NA, NA
TNF-α↓, IL6↓, IFN-γ↓, IL1β↓, PD-L1↓, p‑PKM2↓,
1133- SM,    Salvianolic Acid A, a Component of Salvia miltiorrhiza, Attenuates Endothelial-Mesenchymal Transition of HPAECs Induced by Hypoxia
- in-vitro, Nor, HPAECs
*ROS↓, *p‑Smad1↑, *p‑SMAD5↑, *SMAD2↓, *SMAD3↓, *p‑ERK↓, *p‑Cofilin↓,
1068- SM,    Danshen Improves Survival of Patients With Breast Cancer and Dihydroisotanshinone I Induces Ferroptosis and Apoptosis of Breast Cancer Cells
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vivo, BC, NA - Human, BC, NA
TumCG↓, Ferroptosis↑, GPx4↓, TumVol↓, OS↑, GSH/GSSG↓,
1193- SM,    Cryptotanshinone from the Salvia miltiorrhiza Bunge Attenuates Ethanol-Induced Liver Injury by Activation of AMPK/SIRT1 and Nrf2 Signaling Pathways
- in-vivo, Alcohol, NA - in-vitro, Liver, HepG2
*p‑AMPK↑, *SIRT1↑, *NRF2↑, *CYP2E1↓, *lipoGen↓, *ROS↓, *Inflam↓,
1192- SM,    Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1
- in-vitro, GC, AGS - in-vitro, Liver, HepG3
Hif1a↓, VEGF↓,
1191- SM,    Salvia miltiorrhiza extract inhibits TPA‑induced MMP‑9 expression and invasion through the MAPK/AP‑1 signaling pathw
- in-vitro, BC, MCF-7
Inflam↓, MMP9↓, TumCI↓, AP-1↓, lipidLev↓,
1194- SM,    Salvia miltiorrhiza protects against diabetic nephropathy through metabolome regulation and wnt/β-catenin and TGF-β signaling inhibition
- in-vivo, Diabetic, NA
β-catenin/ZEB1↓, TGF-β↓,
1195- SM,    Salvia miltiorrhiza polysaccharide activates T Lymphocytes of cancer patients through activation of TLRs mediated -MAPK and -NF-κB signaling pathways
- in-vitro, Lung, A549 - in-vitro, Liver, HepG2 - in-vitro, CRC, HCT116
T-Cell↑, TumCP∅, IL4↑, IL6↑, IFN-γ↑, TLR4↑, TLR1↑, TLR2↑, p‑JNK↑, p‑ERK↑, IKKα↑,
1291- SM,    Tanshinone IIA inhibits human breast cancer cells through increased Bax to Bcl-xL ratios
- in-vitro, BC, MDA-MB-231
TumCP↓, TumCCA↑, BAX↑, Bcl-2↓,
4891- Sper,    Spermidine as a promising anticancer agent: Recent advances and newer insights on its molecular mechanisms
- Review, Var, NA - Review, AD, NA
TumCCA↑, TumCP↓, TumCG↓, *Inflam↓, *antiOx↑, *neuroP↑, *cognitive↑, *Aβ↓, *mitResp↑, AntiCan↑, TumCD↑, TumAuto↑, *AntiAge↑, LC3B-II↑, ATG5↑, Beclin-1↑, mt-ROS↑, H2O2↑, Apoptosis↑, *ROS↑, ChemoSen↑, MMP↓, Cyt‑c↑,
4892- Sper,  erastin,    Spermidine inactivates proteasome activity and enhances ferroptosis in prostate cancer
- in-vitro, Pca, PC3 - in-vivo, Pca, NA
Ferroptosis↑, lipid-P↑, Iron↑, eff↑, HO-1↑, NRF2↑, ROS↑, AntiTum↑, eff↓,

Showing Research Papers: 5451 to 5500 of 6108
Prev Page 110 of 123 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6108

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Catalase↓, 2,   Fenton↑, 1,   Ferroptosis↑, 4,   GPx↑, 1,   GPx4↓, 3,   GSH↓, 8,   GSH/GSSG↓, 2,   H2O2↑, 2,   HO-1↑, 1,   HO-1⇅, 1,   Iron↑, 3,   Keap1↑, 1,   lipid-P↑, 3,   MDA↑, 1,   Nrf1↑, 1,   NRF2↓, 2,   NRF2↑, 1,   ROS↓, 1,   ROS↑, 23,   i-ROS↑, 1,   mt-ROS↑, 1,   SOD↓, 1,   SOD1↑, 1,   TrxR↓, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 2,   MMP↓, 9,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

ECAR↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 3,   lactateProd↓, 1,   LDH↓, 1,   LDH↝, 1,   lipidLev↓, 1,   PDK1↓, 2,   PKM2↓, 5,   p‑PKM2↓, 1,   SIRT2↑, 1,  

Cell Death ⓘ

Akt↓, 3,   p‑Akt↓, 1,   p‑Akt↑, 1,   Apoptosis↑, 11,   BAX↑, 3,   Bcl-2↓, 3,   Bcl-2↑, 1,   Casp↑, 2,   Casp3↑, 5,   proCasp3↓, 1,   Casp8↑, 1,   Casp9↑, 2,   Cyt‑c↑, 4,   Ferroptosis↑, 4,   GranB↑, 1,   GSDME↑, 1,   JNK↑, 1,   p‑JNK↑, 1,   Mcl-1↓, 1,   Necroptosis↑, 3,   Perforin↑, 1,   Pyro↑, 1,   RIP1↑, 2,   survivin↓, 1,   TumCD↑, 1,  

Kinase & Signal Transduction ⓘ

p70S6↓, 1,  

Transcription & Epigenetics ⓘ

other↑, 1,   tumCV↓, 2,  

Protein Folding & ER Stress ⓘ

eIF2α↓, 1,   p‑eIF2α↑, 1,   HSP70/HSPA5↑, 1,  

Autophagy & Lysosomes ⓘ

ATG5↑, 1,   Beclin-1↑, 1,   LC3B-II↑, 1,   p62↑, 1,   TumAuto↑, 2,  

DNA Damage & Repair ⓘ

DNAdam↑, 4,   P53↑, 5,   PARP↑, 1,   cl‑PARP↑, 4,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   CDK4↓, 1,   cycD1/CCND1↓, 2,   cycE/CCNE↓, 2,   P21↑, 2,   TumCCA↓, 1,   TumCCA↑, 10,  

Proliferation, Differentiation & Cell State ⓘ

4E-BP1↓, 1,   CSCs↓, 1,   Diff↑, 1,   EMT↓, 1,   ERK↓, 2,   p‑ERK↓, 1,   p‑ERK↑, 3,   GSK‐3β↑, 1,   IGF-1↓, 1,   p‑IGF-1↓, 1,   mTOR↓, 2,   Nanog↓, 1,   OCT4↓, 1,   P70S6K↓, 1,   PI3K↓, 2,   Src↑, 1,   p‑STAT3↓, 1,   TumCG↓, 8,  

Migration ⓘ

AP-1↓, 1,   Ca+2↑, 2,   CD11b↑, 1,   E-cadherin↑, 1,   ITGB1↓, 1,   Ki-67↓, 1,   MMP13↓, 1,   MMP2↓, 1,   MMP9↓, 2,   N-cadherin↓, 1,   PAK1↓, 1,   RIP3↑, 1,   Snail↓, 1,   TGF-β↓, 1,   TumCI↓, 4,   TumCMig↓, 3,   TumCP↓, 12,   TumCP∅, 1,   TumMeta↓, 1,   VCAM-1↓, 1,   Vim↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 2,   p‑EGFR↓, 1,   Hif1a↓, 4,   KDR/FLK-1↓, 1,   TAMS↝, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

CD14↑, 1,   COX2↓, 1,   Gal1↑, 1,   HMGB1↓, 1,   IFN-γ↓, 1,   IFN-γ↑, 1,   IKKα↑, 1,   IL1β↓, 1,   IL4↑, 1,   IL6↓, 2,   IL6↑, 1,   Inflam↓, 1,   JAK1?, 1,   p‑JAK1↓, 1,   p‑JAK2↓, 1,   NF-kB↓, 2,   NK cell↑, 1,   PD-L1↓, 1,   T-Cell↑, 1,   TLR1↑, 1,   TLR2↑, 1,   TLR4↑, 1,   TNF-α↓, 1,  

Cellular Microenvironment ⓘ

ADAM17↓, 1,   pH↝, 1,  

Hormonal & Nuclear Receptors ⓘ

ERα/ESR1↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   ChemoSen↑, 4,   Dose↝, 1,   eff↓, 8,   eff↑, 6,   eff⇅, 1,   eff↝, 1,   Half-Life↝, 2,   selectivity↑, 7,  

Clinical Biomarkers ⓘ

EGFR↓, 2,   p‑EGFR↓, 1,   ERα/ESR1↓, 1,   IL6↓, 2,   IL6↑, 1,   Ki-67↓, 1,   LDH↓, 1,   LDH↝, 1,   PD-L1↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 2,   AntiTum↑, 1,   cardioP↑, 1,   chemoP↑, 1,   OS↑, 1,   TumVol↓, 1,  
Total Targets: 182

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   Catalase↑, 1,   CYP2E1↓, 1,   GPx↑, 1,   GSH↑, 2,   HO-1↑, 2,   MPO↓, 3,   NRF2↑, 5,   ROS↓, 6,   ROS↑, 1,   SOD↑, 3,  

Mitochondria & Bioenergetics ⓘ

mitResp↑, 1,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 2,   AMPK↑, 1,   p‑AMPK↑, 1,   lipoGen↓, 1,   SIRT1↑, 1,  

Cell Death ⓘ

p‑Akt↑, 1,   Apoptosis↓, 1,   BAX↓, 2,   Bcl-2↑, 3,   Casp3↓, 1,   JNK↓, 1,   p38↓, 1,  

Transcription & Epigenetics ⓘ

other↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↓, 1,   p‑ERK↓, 1,   p‑PTEN↓, 1,   STAT3↑, 1,  

Migration ⓘ

p‑Cofilin↓, 1,   E-sel↓, 1,   p‑Smad1↑, 1,   SMAD2↓, 1,   SMAD3↓, 1,   p‑SMAD5↑, 1,   VCAM-1↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   ICAM-1↓, 1,   IFN-γ↓, 1,   p‑IKKα↓, 1,   IL1β↓, 2,   IL6↓, 2,   Inflam↓, 5,   NF-kB↓, 1,   NF-kB↑, 1,   TNF-α↓, 3,  

Synaptic & Neurotransmission ⓘ

BDNF↑, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 2,   Dose↝, 1,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 2,   AST↓, 2,   IL6↓, 2,  

Functional Outcomes ⓘ

AntiAge↑, 1,   cognitive↑, 3,   hepatoP↑, 2,   neuroP↑, 4,   toxicity↓, 3,   toxicity∅, 1,  
Total Targets: 61

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page